pre-IPO PHARMA

COMPANY OVERVIEW

Exscientia is at the forefront of small molecule drug discovery. They are the first company to automate drug design, surpassing conventional human endeavour. Their AI driven systems actively learn best practice from vast repositories of discovery data and are further enhanced with knowledge acquired from seasoned drug hunters.


LOCATION

  • Oxford, , UK
  • Dundee, , UK

  • THERAPEUTIC AREAS

  • Immunology
  • Metabolic Disorders
  • Neurological DIsorders
  • Oncology

  • WEBSITE

    https://www.exscientia.co.uk/


    CAREER WEBSITE

    None


    SOCIAL MEDIA


    INVESTORS



    PRESS RELEASES


    Oct 5, 2021

    Exscientia Announces Closing of $510.4 Million Aggregate Financing, Consisting of $350.4 Million Upsized Initial Public Offering With Full Exercise of Underwriters’ Option to Purchase Additional ADSs and $160.0 Million Concurrent Private Placement


    Sep 30, 2021

    Exscientia Announces Pricing of $304.7 Million Upsized Initial Public Offering and $160.0 Million Concurrent Private Placements


    Sep 8, 2021

    Exscientia Enters $70M Collaboration to Develop Antiviral Therapeutics Against Coronavirus and Other Viruses With Pandemic Potential


    Aug 18, 2021

    Bristol Myers Squibb Exercises Option to Develop Exscientia’s AI-designed, Immune-modulating Drug Candidate


    Aug 4, 2021

    Exscientia Builds Automated Laboratories in Oxford to Expand Pipeline


    For More Press Releases


    Google Analytics Alternative